Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of utidelone-based treatment in advanced solid tumors after standard treatment failure
CTR20201803Phase 2Active
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Mar 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in Nonhematologic neoplasms, gastric cancer (GC), gastroesophageal junction adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Started Mar 2021; status: active.
02
Drugs
utidelone
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)gastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20201803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201803.